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assumed a constant change in utility occurs with a one unit
change in BMI. However, recent studies demonstrate the magni-
tude of changes in utility scores may vary depending on: a)
whether a patient is valuing weight loss or gain; b) whether a
smaller or larger change in body weight is being evaluated; and
c) baseline BMI. CONCLUSIONS: Various utility values associ-
ated with body weight using different methodologies have been
published. Careful consideration should be given to determine
the most appropriate utility values to use in cost utility analyses
of T2DM therapies.
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OBJECTIVES: To develop a multidimensional speciﬁc question-
naire of factors related to weight loss therapies proposed for the
assessment of therapy success or failure. METHODS: Three focus
groups of patients where debriefed and an expert panel gathered
relevant issues and converted them into 54 items around 9 dimen-
sions: Alimentary Habits, Expectations towards Therapy, Effort
and Concern, Emotion, Conﬁdence, Believes, Motivation towards
Physical Exercise, Motivation towards Weight Loss, and Per-
ceived Control. Comprehension and legibility were questioned in
a pilot sample. A ﬁrst item reduction was done to avoid redun-
dancies and to establish content agreement. Item reduction was
carried out in a sample of patients using factor analysis. Feasi-
bility, reliability, content validity and factor validity were assessed.
RESULTS: A panel of 11 practitioners and researchers, belong-
ing to different health centers in the Community of Madrid gath-
ered 3 samples: One sample of 8 chronic patients participating in
3 focus groups; a sample of 8 patients to assess feasibility; a sample
of 121 patients for item reduction. A ﬁrst conceptual reduction
conveyed a 32 item version. After measurement in a representa-
tive sample a ﬁnal 17 items form was accepted. Items were
arranged around 6 dimensions: Impulsiveness, External Locus of
Control, Internal Locus of Control, Emotiveness, Motivation
towards Therapy and Exercise, and Personal Image. Overall
Cronbach’s a was 0.772 (ICC 95% conﬁdence interval =
0.698–0.835). The 6 dimensions solution accounted for 71.2%
of variance, with all eigenvalues above 1. CONCLUSIONS: The
new questionnaire is a very short inventory of factors which might
have screening properties in order to forecast the efﬁcacy of
weight loss therapies. Although further prospective research is
being carried out in order to assess predictive validity, basic psy-
chometric properties are good as a baseline model. Resulting
dimensions are meaningful and well formed.
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OBJECTIVES: To evaluate the impact of the ﬁrst selective
cannabinoid type 1 (CB1) receptor blocker, rimonabant, devel-
oped for the management of cardiometabolic risk factors, on
health related quality of life (HRQOL) in overweight/obese
patients with type 2 diabetes. METHODS: A total of 1045
patients with type 2 diabetes were randomized in a double-blind
trial and received either rimonabant 5 mg, 20 mg or placebo.
Patients completed the Impact of Weight on Quality of Life-Lite
(IWQOL-Lite), a validated 31-item questionnaire speciﬁcally
designed for HRQOL assessment in obesity, and reported days
missed from work at baseline and every 3-months up to 1 year.
Analyses were performed on mean score changes from baseline
to 1 year in the ITT population. Clinical meaningfulness was
assessed using the Effect Size (ES) method, which is a measure
of change over time that takes into account the variability within
the sample at baseline. RESULTS: At 1 year, patients adminis-
tered rimonabant 20 mg once daily (N = 339) reported signiﬁ-
cantly greater improvement (p < 0.001, and p = 0.03 for Work)
in IWQOL-Lite total score and 3 out of 5 domains (Physical
Function, Self-esteem and Work) than patients in the placebo
group (N = 348) (no signiﬁcant change in Sexual Life and Public
Distress). These improvements were clinically meaningful (ES >
0.2). Also, there was a trend to fewer days missed from work
reported by patients on rimonabant 20 mg (720 days) compared
with those on placebo (1242 days) over the study period (p =
0.2 based on the number of patients with at least 1 day missed
from work). CONCLUSIONS: HRQOL results showed both a
statistically signiﬁcant and clinically meaningful improvement in
total score and also several domains (Physical Function, Self-
esteem and Work) of the IWQOL-Lite questionnaire, with
rimonabant versus placebo after a once daily administration of
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OBJECTIVES: To assess the efﬁcacy of a new, ready-to-use intra-
venous paracetamol in postoperative pain management in com-
parison with placebo, oral paracetamol, propacetamol and other
NSAIDs. METHODS: Electronic databases search (Medline—
PubMED, EMBASE, Cochrane Database of Systematic Reviews,
Cochrane Central Register of Controlled Trials, Core Biomedical
Collection), until March 2006, was conducted for randomised
controlled trials on postoperative pain management with intra-
venous paracetamol in monotherapy or in combined treatment.
Only full text articles published in peer-reviewed journals were
accepted. Study results were combined in meta-analysis plots
using RevMan, where appropriate. RESULTS: Six studies met the
inclusion criteria: four compared intravenous paracetamol with
placebo, one with oral paracetamol, two with propacetamol and
one with metamizole. All studies were methodologically of high
quality (average 4.83 points in Jadad scale). Treatment with intra-
venous paracetamol was signiﬁcantly superior to placebo in pain
relief, pain intensity difference, reduction of opioid consumption
and patient treatment satisfaction (by 22% to 325%). Patients
treated with intravenous paracetamol received less opioids than
treated with oral paracetamol, whereas incidence of postopera-
tive nausea and vomiting did not differ. No signiﬁcant difference
was obtained between intravenous paracetamol and propaceta-
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mol considering pain relief, pain intensity difference, patient’s
global treatment satisfaction and between intravenous paraceta-
mol and metamizole on pain scores and pain scores on coughing.
Intravenous paracetamol had safety proﬁle similar to placebo.
Adults treated with intravenous paracetamol had 9 times lower
risk of adverse events (RR = 0.11; 95%CI: 0.05–0.24) and 30
times lower risk of infusion site reactions (RR = 0.03; 95%CI:
0.01–0.16), comparing with propacetamol. CONCLUSIONS:
Intravenous paracetamol is an effective drug in postoperative pain
management in children and adults as superior to oral paraceta-
mol and placebo. Its efﬁcacy is comparable to propacetamol and
metamizole, with better safety proﬁle.
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OBJECTIVE: To compare the efﬁcacy and tolerability of dulox-
etine (DLX) with pregabalin (PGB) and gabapentin (GBP) for the
treatment of diabetic peripheral neuropathic pain (DPNP).
METHODS: We searched PubMed, Ovid, CENTRAL databases
and regulatory websites for randomized, double-blind, placebo-
controlled, parallel group or crossover clinical trials (RCTs)
assessing DLX, PGB and GBP in DPNP. Study arms using
approved dosages with assessments after 5–13 weeks were eligi-
ble. Efﬁcacy criteria were: reduction in 24-hour pain severity
(24hPS) for all three drugs, and response rate (>50% pain reduc-
tion) and Patient’s Global Impression of Improvement/Change
(PGI-I/C) for DLX and PGB only. Tolerability criteria were: 
discontinuation, diarrhoea, dizziness, headache, nausea and
somnolence. Pooled ﬁxed- and random-effects analyses were
conducted on endpoints reported in at least two studies of each
drug. Each drug was compared with placebo. DLX was com-
pared indirectly with PGB and GBP by meta-regression.
RESULTS: Three studies of DLX, 6 of PGB and 2 of GBP were
eligible. Between-study heterogeneity was insigniﬁcant. In
random-effects and ﬁxed-effects analyses, all drugs were supe-
rior to placebo for all efﬁcacy parameters, with some tolerabil-
ity trade-offs. Indirect comparison of DLX with PGB found no
differences in 24hPS, but signiﬁcant differences in PGI-I/C,
favouring PGB, and dizziness, favouring DLX were apparent.
Comparing DLX and GBP, there were no statistically signiﬁcant
differences. CONCLUSIONS: From the few studies available for
indirect comparison, DLX shows comparable efﬁcacy and toler-
ability to GBP and PGB in DPNP. Duloxetine provides an impor-
tant treatment option for this disabling condition.
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OBJECTIVES: Comparison of safety of intravenous metamizole,
ketoprofen and paracetamol based on data from WHO Pro-
gramme for International Drug Monitoring. METHODS: The
data from countries participating in the World Health Organi-
zation Programme for International Drug Monitoring are col-
lected and maintained, on behalf of the WHO, by the Uppsala
Monitoring Centre, in the Vigibase. An analysis of data on
adverse events (AE) of intravenous formulations of metamizole,
ketoprofen and paracetamol, reported to Vigibase, from Euro-
pean countries since 1968 up to 29th January 2006 (ref: ER
132/2005), was performed. RESULTS: One thousand three
hundred seventy one individual case reports of metamizole
adverse events were registered in the Vigibase, compared to 367
and 69 for ketoprofen and paracetamol, respectively. Serious AE
were reported in 29 metamizole cases, 47—ketoprofen and none
for paracetamol. There were 15 death cases registered for
metamizole, 1 for ketoprofen and paracetamol. Hematologic dis-
orders were reported in 187 metamizole cases, i.e. 6 and 31 times
more common then for ketoprofen and paracetamol therapy,
respectively. Most frequent AE reports for metamizole were: ana-
phylactic shock (79 cases versus 6 and 3 with ketoprofen and
paracetamol, respectively), agranulocytosis (77 vs 3 vs 1), rash
erythematous (63 vs 26 vs 3), hypotension (54 vs 6 vs 3), pruri-
tus (53 vs 10 vs 1), rash (51 vs 17 vs 0), leucopenia (48 vs 6 vs
2) and circulatory failure (48 vs 5 vs 2). CONCLUSIONS: Intra-
venous therapy with paracetamol is safer than with ketoprofen
or metamizole, concerning total number of reported adverse
events, number of reported serious adverse events and number
of hematologic disorders. Death cases were reported 15 times
more often with metamizole than with either paracetamol or
ketoprofen.
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Chronic lower back pain (CLBP) is a major economic burden on
individuals, health care system and society as a whole. Spinal
fusion surgery is recommended in patients with persistent pain.
Most lumbar spinal fusion surgery involves the use of bone auto-
graft from patient’s iliac crest, which implies increased co-mor-
bidity. InductOs® is indicated for single-level (L4–S1) anterior
lumbar spine fusion as a substitute for autogenous bone graft in
adults with degenerative disc disease (DDD). OBJECTIVE: To
evaluate the potential economic beneﬁts of InductOs® compared
to autograft, in spinal fusions in patients with DDD in Spain.
METHODS: An analytic decision tree model was developed in
order to simulate the clinical pathways of a cohort of 1000 sim-
ulated patients with DDD. The analysis was performed from the
perspective Spanish National Health System (payer), with a time
horizon of 2 years. Clinical and economical data were retrieved
from published studies and ofﬁcial tariffs, validated by a clini-
cian trained in the management of these patients in the Spanish
setting. RESULTS: In Spain, the use of InductOs® leads to a
reduction in operation times and length of stay resulting in
savings of €930 per patient, to a reduction of revisional spinal
procedures resulting in further savings of €428 per patient, and
to a faster return to work by an average of 54 days, resulting in
additional savings of €2304 per patient from sickness-leave pay-
ments avoided. These savings offset the upfront cost of Induc-
tOs® of 2799 resulting in net cost savings of €863 per case
treated, as compared to standard care. CONCLUSION: Adding
